Purpose: To evaluate the therapeutic benefit of self-retained cryopreserved amniotic membrane in conjunction with oral antiviral therapy in herpetic epithelial keratitis.
H erpes simplex virus (HSV) infection is an epidemiologically important cause of infectious and inflammatory
disease in the world. 1 Among all ocular manifestations of HSV, epithelial keratitis is the most frequent and conspicuous. After HSV corneal infection, epithelial cells initiate an immune response and inflammation. 2 Activated macrophages produce cytokines such as interferon-alpha/beta (IFN-a/b) and are the main source of interleukin-12 (IL-12) and nitric oxide synthase to produce NO (reviewed in Ref. 3) . T helper 1 cytokines such as IFN-gamma (IFN-g) and IL-2 are elevated to enhance proinflammatory responses. 4 Collectively, these robust immune responses and toxic metabolites could cause serious damage to other corneal layers including corneal nerves. 5 Therefore, it is important to formulate an effective strategy to accelerate restoration of corneal health by promptly controlling viral infection, minimizing immune-mediated damage, facilitating corneal epithelial regeneration, and preventing subsequent corneal scarring or neurotropic sequelae.
Antiviral medications are commonly used to hinder HSV replication and halt active viral infection of the cornea. 6 Oral antiviral agents are as effective as topical antiviral agents in treatment of HSV keratitis, whereas topical antivirals may have toxic effects to the corneal epithelium. 7 Additional use of topical corticosteroids or other immunosuppressive treatment of HSV epithelial keratitis is complicated by exacerbating dendritic to geographic epithelial keratitis, reactivating latent virus to trigger recurrence, and inducing side effects such as secondary bacterial infection, corneal melt, elevation of the intraocular pressure, or cataract. 8 In this regard, it is innovative to consider using cryopreserved amniotic membrane (CAM) by deploying its antiinflammatory, antiscarring, and antiangiogenic effects known for treating many ocular surface diseases. 9 This notion is further strengthened by many studies showing that CAM can effectively control inflammation in HSV stromal keratitis in a murine model of HSV1 necrotizing keratitis [10] [11] [12] [13] and in human epithelial and stromal HSV keratitis with [14] [15] [16] or without [17] [18] [19] [20] [21] adjuvant antiviral therapy.
To facilitate early intervention by CAM, a sutureless approach through the placement of the PROKERA (BioTissue, Inc, Miami, FL) has been developed. Within the PROKERA family, the PROKERA Slim (PKS) differs from the PROKERA Classic in the ring design where the same CAM is fastened by 1 polycarbonate ring and an elastic band for the former, whereas by 2 polycarbonate rings for the latter. Consequently, the CAM enwraps the entire ring set in the former but partially in the latter to ensure comfort. In this article, we present 4 cases of HSV epithelial keratitis to further illustrate how the PKS can facilitate the ease of early intervention to accelerate restoration of corneal health.
PATIENTS AND METHODS
This study was approved by the Ethics Committee of the Ocular Surface Research and Education Foundation (Miami, FL) according to the tenets of the Declaration of Helsinki to retrospectively review 4 consecutive patients with HSV epithelial keratitis seen at the Ocular Surface Center (Miami, FL) from January 2012 to December 2016. The diagnosis of HSV infection was based primarily on the clinical findings. Three patients [case 1 (Fig. 1A) , case 2 (Fig. 1B) , and case 4 ( Fig. 1C) ] had active dendritic epithelial keratitis presenting with multiple linear branches and terminal bulbs, whereas one patient (case 3) (Fig. 1D ) developed a macrocorneal ulcer of geographic epithelial keratitis. HSV epithelial keratitis was typically unilateral without involvement of the contralateral eye. Table 1 summarizes the patients' demographics, ocular comorbidity, number of previous episodes of epithelial keratitis, concomitant medication, and clinical manifestations including symptoms and signs at the presentation. Conjunctival inflammation was graded as none (0), mild (1), moderate (2), and severe (3). Corneal surface integrity was scored as clear (0), scattered superficial punctuate keratitis (SPK; 1+), moderate SPK (2+), and diffuse SPK or with corneal epithelial defects (3+). Debridement to remove the loosened and infected epithelium was performed in 3 patients except case 4 with a dry Weck-Cel sponge (Beaver-Visitec International, Inc, Waltham, MA). Self-retaining CAM through the PKS was placed in all 4 patients while receiving oral acyclovir 200 mg 5 times daily and topical 0.3% ofloxacin (Allergan, Irvine, CA) 3 times daily. The PKS was removed on corneal epithelial healing and was followed by a bandage contact lens as needed. Descriptive statistics for continuous variables are reported as mean 6 SD and analyzed using SPSS software, version 20.0 (SPSS Inc, Chicago, IL). P , 0.05 was considered statistically significant.
RESULTS
As summarized in Table 1 , these 4 patients included 3 women and 1 man with an average age of 71.3 6 9.9 years. Except for case 4, which was the first occurrence, 3 had a history of herpetic epithelial keratitis without stromal keratitis or blepharoconjunctivitis. Among these 3, 2 patients (cases 1 and 2) experienced multiple recurrent episodes, whereas one (case 3) had only 1 previous episode that triggered corneal graft failure, thus requiring repeated penetrating keratoplasty. For these 3 patients, herpetic epithelial keratitis recurred in an average of 6.5 6 2.1 months while continuously receiving oral antiviral therapy (cases 1 and 2) or 53 months after penetrating keratoplasty combined with oral antiviral treatment and topical At presentation, these patients complained of ocular pain, irritation, blurred vision, photophobia, redness, and tearing. Their vision measured by logarithm of the minimum angle of resolution was all reduced (Table 1) . Cases 1, 2, and 4 presented with a typical dendritic lesion consisting of multiple linear branches and terminal bulbs, whereas case 3 had a geographic ulcer (Fig. 1) . Epithelial debridement followed by placement of the PKS was performed uneventfully in all cases (Fig. 1) . After an average PKS placement duration of 5 6 3.7 days (Fig. 1) in conjunction with topical ofloxacin and oral acyclovir, all patients reported significant relief of symptoms, rapid corneal epithelialization, and reduction of ocular surface inflammation (Table 1) . Single placement of the PKS for 4, 5, 10, and 1 day(s) achieved complete epithelialization in 4, 5, 10, and 4 days, respectively, in these 4 patients, based on the medical record available, although all patients were not seen daily (Fig. 1) . The visual acuity was also improved in all eyes from 0.7 6 0.7 to 0.4 6 0.7 logarithm of the minimum angle of resolution (P = 0.2). They remained symptom-free during a follow-up period of 2.7 to 50.8 (20.3 6 21.7) months.
DISCUSSION
Our results show that CAM through the placement of the PKS in conjunction with oral acyclovir accelerates recovery of a normal corneal epithelium in 4 patients with primary and recurrent HSV epithelial keratitis. Such a therapeutic benefit is consistent with what has been reported using CAM in an experimental murine model of HSV1 necrotizing keratitis, [10] [11] [12] [13] and in patients with HSV stromal keratitis [14] [15] [16] [17] [18] [19] [20] [21] or epithelial keratitis. 14, 16 Our study further demonstrates that the sutureless approach through placement of the PKS facilitates the ease of early intervention to simplify delivery of these therapeutic benefits of CAM. The sutureless approach of CAM is important because it can be placed in-office so as to avoid delays inherent to scheduling surgical procedures, sutureinduced inflammation, and the risk of surgical complications as well as to facilitate timely intervention.
The therapeutic benefit observed herein in reducing inflammation and scarring as well as to promote epithelial wound healing is consistent with what has been summarized recently (reviewed in Refs. 22 and 23) . In addition to the nonspecific antiviral immunity yielded by the endogenous IFN in the human placenta, 24, 25 recent studies identified that the broad antiinflammatory action in CAM applies to activated but not resting neutrophils, 26, 27 macrophages, 27 and lymphocytes 26 extending from innate to adaptive immune responses. The active matrix, termed heavy chain-hyaluronic acid/pentraxin 3 (HC-HA/PTX3), in CAM polarized macrophages toward the M2 including wound-healing (M2b) and antiinflammatory (M2c) phenotype to significantly downregulate IL-12, TNF-a, and nitric oxide synthase as well as to reduce proinflammatory cytokines IFN-g and IL-2. 28 Importantly, CAM is rich in nerve growth factor, which not only reduces inflammation but also potentially facilitates return of corneal nerves. 9 Collectively, these actions explain why the PKS in conjunction with oral acyclovir accelerates restoration of a normal corneal epithelium while reducing the potential adverse event from topical corticosteroids or other immunosuppressive treatments.
The average epithelialization duration of dendritic keratitis in our cases was 4.3 6 0.6 days for dendritic keratitis and 5.75 6 2.8 days for dendritic and geographic keratitis. The overall healing time seemed to be shorter compared with the median time to healing with different antiviral-treated dendritic and 
